Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ3AC0)

• Drug Name: BW284C51 Drug Info
• Synonyms: 4-(5-{4-[Dimethyl(prop-2-enyl)ammonio]phenyl}-3-oxopentyl)-N,N-dimethyl-N-prop-2-enylbenzenaminium; BW284c51; CHEMBL140020; BW-28C51; EBW; 4-(5-{4-[DIMETHYL(PROP-2-ENYL)AMMONIO]PHENYL}-3-OXOPENTYL)-N,N-DIMETHYL-N-PROP-2-ENYLBENZENAMINIUM; CHEMBL464538; SCHEMBL7449688; GTPL6600; AC1L1B98; BDBM10624; ZAEXMNKDGJNLTA-UHFFFAOYSA-N; ZINC3814201; NCGC00247016-01; 1,5-Bis[4-(allyldimethylaminio)phenyl]pentane-3-one; 1,5-bis(4-allyldimethylammoniumphenyl)-pentan-3-one dibromide; 4,4'-(3-oxopentane-1,5-diyl)bis(N,N-dimethyl-N-prop-2-en-1-ylanilinium)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 1338
  TTD Drug ID: DMQ3AC0

Molecule-Related Drug Atlas

Drug(s) Targeting Acetylcholinesterase (AChE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[3]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[4]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[5]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[6]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[7]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[8]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[9]
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[10]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[11]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6600).
• [2] Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res. 2003 Apr;28(3-4):515-22.
• [3] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [5] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [6] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [7] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [8] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [10] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [11] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [12] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.